Ellen Apperloo

Ellen Apperloo is a researcher at the University of Groningen, specializing in the intersection of diabetes and kidney disease. Her work focuses on evaluating pharmacotherapies like semaglutide, tirzepatide, and SGLT2 inhibitors in managing Type 2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD), particularly examining biomarkers such as albuminuria and kidney oxygenation.

• Key Research Areas: GLP-1 receptor agonists, diabetic kidney disease, obesity-related CKD, clinical trial analysis
• Current Affiliation: University of Groningen (medical/pharmacological research focus)

Her recent publications highlight investigations into semaglutide's effects on kidney function across varying baseline parameters, combination therapies for improving renal outcomes, and tirzepatide's role in reducing albuminuria. These studies align with UN Sustainable Development Goals (SDGs) for improved health outcomes.

• Notable Trends: Integration of metabolic and renal endpoints in clinical trials, emphasis on non-diabetic CKD populations, translational pharmacology research

She collaborates internationally with experts in endocrinology and nephrology, with her work widely disseminated through social media platforms and academic networks like Mendeley.